Medochemie’s Yasser Sabra gives a fascinating insight into the branded generic and value added medicine field today, including why the COVID-19 pandemic could lead to a reappraisal of medicine repurposing. Sabra also touches on the firm’s operations in the Middle East’s biggest market of Saudi Arabia, explaining why the Saudi localisation rush and associated high costs will soon settle down and how Medochemie has managed to establish itself as a key partner to the Saudi MoH, especially for its injectable antibiotic range.
Could you begin by introducing Medochemie Ltd to our international audience?
Medochemie Ltd is a European pharmaceutical company that develops, manufactures, and commercialises off-patent medicines, also known as Branded Generics, and Value Added Medicines.
We have 45 years of history as a pharmaceutical manufacturer; the company was established back in 1976 by a visionary medical doctor, Dr Andreas Pittas, who realised the importance of local manufacturing of medicines in Cyprus. Since then we have adhered to the same company mission and philosophy:
To provide every human being across the globe with quality and affordable drug treatment in a manner that supports sustainability
